- call +1-201-465-4211
- email sales@mrinsights.biz
Colorectal cancer is a malignant tumor that starts in the cells of the colon or the rectum while it takes place in anus in case of anal cancer.
Scope of the Report:
Rising prevalence of anal and colorectal cancer due to poor lifestyles such as obesity and tobacco consumption has been the major factor driving the market growth.
The global Anal and Colorectal Cancer market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Anal and Colorectal Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Anal and Colorectal Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Anal and Colorectal Cancer market by product type and applications/end industries.
Market Segment by Companies, this report covers
Abbott Diagnostics
Advaxis
Alere
Amgen
Atara Biotherapeutics
Bayer
Metabiomics
Beckman Coulter
BeiGene
Boehringer Ingelheim
Clinical Genomics
EDP Biotech
Eli Lilly
Epigenomics
Exact Sciences
Genomictree
Immunovaccine
ISA Pharmaceuticals
Merck
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Surgery
Radiation therapy
Colorectal cancer chemotherapy
Targeted therapy
Immunotherapy
Market Segment by Applications, can be divided into
Hospitals
Ambulatory surgery centers
Cancer research centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Anal and Colorectal Cancer Market Overview
1.1 Product Overview and Scope of Anal and Colorectal Cancer
1.2 Classification of Anal and Colorectal Cancer by Types
1.2.1 Global Anal and Colorectal Cancer Revenue Comparison by Types (2017-2023)
1.2.2 Global Anal and Colorectal Cancer Revenue Market Share by Types in 2017
1.2.3 Surgery
1.2.4 Radiation therapy
1.2.5 Colorectal cancer chemotherapy
1.2.6 Targeted therapy
1.2.7 Immunotherapy
1.3 Global Anal and Colorectal Cancer Market by Application
1.3.1 Global Anal and Colorectal Cancer Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory surgery centers
1.3.4 Cancer research centers
1.4 Global Anal and Colorectal Cancer Market by Regions
1.4.1 Global Anal and Colorectal Cancer Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Anal and Colorectal Cancer Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Anal and Colorectal Cancer Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anal and Colorectal Cancer Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Anal and Colorectal Cancer Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anal and Colorectal Cancer Status and Prospect (2013-2023)
1.5 Global Market Size of Anal and Colorectal Cancer (2013-2023)
2 Manufacturers Profiles
2.1 Abbott Diagnostics
2.1.1 Business Overview
2.1.2 Anal and Colorectal Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbott Diagnostics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.2 Advaxis
2.2.1 Business Overview
2.2.2 Anal and Colorectal Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Advaxis Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.3 Alere
2.3.1 Business Overview
2.3.2 Anal and Colorectal Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Alere Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.4 Amgen
2.4.1 Business Overview
2.4.2 Anal and Colorectal Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Amgen Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.5 Atara Biotherapeutics
2.5.1 Business Overview
2.5.2 Anal and Colorectal Cancer Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Atara Biotherapeutics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bayer
2.6.1 Business Overview
2.6.2 Anal and Colorectal Cancer Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bayer Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.7 Metabiomics
2.7.1 Business Overview
2.7.2 Anal and Colorectal Cancer Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Metabiomics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.8 Beckman Coulter
2.8.1 Business Overview
2.8.2 Anal and Colorectal Cancer Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Beckman Coulter Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.9 BeiGene
2.9.1 Business Overview
2.9.2 Anal and Colorectal Cancer Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 BeiGene Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.10 Boehringer Ingelheim
2.10.1 Business Overview
2.10.2 Anal and Colorectal Cancer Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Boehringer Ingelheim Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.11 Clinical Genomics
2.11.1 Business Overview
2.11.2 Anal and Colorectal Cancer Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Clinical Genomics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.12 EDP Biotech
2.12.1 Business Overview
2.12.2 Anal and Colorectal Cancer Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 EDP Biotech Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.13 Eli Lilly
2.13.1 Business Overview
2.13.2 Anal and Colorectal Cancer Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Eli Lilly Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.14 Epigenomics
2.14.1 Business Overview
2.14.2 Anal and Colorectal Cancer Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Epigenomics Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.15 Exact Sciences
2.15.1 Business Overview
2.15.2 Anal and Colorectal Cancer Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Exact Sciences Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.16 Genomictree
2.16.1 Business Overview
2.16.2 Anal and Colorectal Cancer Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Genomictree Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.17 Immunovaccine
2.17.1 Business Overview
2.17.2 Anal and Colorectal Cancer Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Immunovaccine Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.18 ISA Pharmaceuticals
2.18.1 Business Overview
2.18.2 Anal and Colorectal Cancer Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 ISA Pharmaceuticals Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.19 Merck
2.19.1 Business Overview
2.19.2 Anal and Colorectal Cancer Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Merck Anal and Colorectal Cancer Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anal and Colorectal Cancer Market Competition, by Players
3.1 Global Anal and Colorectal Cancer Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Anal and Colorectal Cancer Players Market Share
3.2.2 Top 10 Anal and Colorectal Cancer Players Market Share
3.3 Market Competition Trend
4 Global Anal and Colorectal Cancer Market Size by Regions
4.1 Global Anal and Colorectal Cancer Revenue and Market Share by Regions
4.2 North America Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
4.3 Europe Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
4.5 South America Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
5 North America Anal and Colorectal Cancer Revenue by Countries
5.1 North America Anal and Colorectal Cancer Revenue by Countries (2013-2018)
5.2 USA Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
5.3 Canada Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
5.4 Mexico Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
6 Europe Anal and Colorectal Cancer Revenue by Countries
6.1 Europe Anal and Colorectal Cancer Revenue by Countries (2013-2018)
6.2 Germany Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
6.3 UK Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
6.4 France Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
6.5 Russia Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
6.6 Italy Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Anal and Colorectal Cancer Revenue by Countries
7.1 Asia-Pacific Anal and Colorectal Cancer Revenue by Countries (2013-2018)
7.2 China Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
7.3 Japan Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
7.4 Korea Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
7.5 India Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
8 South America Anal and Colorectal Cancer Revenue by Countries
8.1 South America Anal and Colorectal Cancer Revenue by Countries (2013-2018)
8.2 Brazil Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
8.3 Argentina Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
8.4 Colombia Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Anal and Colorectal Cancer by Countries
9.1 Middle East and Africa Anal and Colorectal Cancer Revenue by Countries (2013-2018)
9.2 Saudi Arabia Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
9.3 UAE Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
9.4 Egypt Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
9.5 Nigeria Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
9.6 South Africa Anal and Colorectal Cancer Revenue and Growth Rate (2013-2018)
10 Global Anal and Colorectal Cancer Market Segment by Type
10.1 Global Anal and Colorectal Cancer Revenue and Market Share by Type (2013-2018)
10.2 Global Anal and Colorectal Cancer Market Forecast by Type (2018-2023)
10.3 Surgery Revenue Growth Rate (2013-2023)
10.4 Radiation therapy Revenue Growth Rate (2013-2023)
10.5 Colorectal cancer chemotherapy Revenue Growth Rate (2013-2023)
10.6 Targeted therapy Revenue Growth Rate (2013-2023)
10.7 Immunotherapy Revenue Growth Rate (2013-2023)
11 Global Anal and Colorectal Cancer Market Segment by Application
11.1 Global Anal and Colorectal Cancer Revenue Market Share by Application (2013-2018)
11.2 Anal and Colorectal Cancer Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory surgery centers Revenue Growth (2013-2018)
11.5 Cancer research centers Revenue Growth (2013-2018)
12 Global Anal and Colorectal Cancer Market Size Forecast (2018-2023)
12.1 Global Anal and Colorectal Cancer Market Size Forecast (2018-2023)
12.2 Global Anal and Colorectal Cancer Market Forecast by Regions (2018-2023)
12.3 North America Anal and Colorectal Cancer Revenue Market Forecast (2018-2023)
12.4 Europe Anal and Colorectal Cancer Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Anal and Colorectal Cancer Revenue Market Forecast (2018-2023)
12.6 South America Anal and Colorectal Cancer Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Anal and Colorectal Cancer Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Anal and Colorectal Cancer Picture
Table Product Specifications of Anal and Colorectal Cancer
Table Global Anal and Colorectal Cancer and Revenue (Million USD) Marke
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
